investors

In March 2008, the Company closed its Series B financing round for € 25 M (US$ 38 M). The round was led by OrbiMed Advisors LLC with Novo Nordisk A/S as co-investor via its Novo Nordisk Biotech Fund. All existing investors participated in this round as well.

Through its Series A (2002) and A1 (2006) financing rounds the Company received total financing of € 18 M from international life science investors Global Life Science Ventures (lead), Gilde Healthcare Partners (co-lead), Forbion Capital Partners, BayTech Venture Capital, Bio-M, TCB, KfW and BayernKapital.